drugset / Trial / NCT01369511
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA).
Timeline
- Start
- 2011-07
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LANDOGROZUMAB | Monoclonal antibody | 35 mg | Subcutaneous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 105 mg | Subcutaneous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 315 mg | Subcutaneous |